Lilly Advances Eloralintide Into Phase 3, Expanding Its Obesity Drug Ambitions

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.

The Phase 3 study “A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin” will test if Lilly’s new drug can safely improve weight outcomes in adults with ongoing obesity or overweight who are already on weekly incretin therapy, with or without type 2 diabetes.

Eloralintide (LY3841136) is a once weekly injection given under the skin. It is designed to be added on top of existing weekly incretin drugs to further reduce weight in people who have not reached their goals, while a placebo group will help show how much extra benefit the drug may offer.

The trial is an interventional Phase 3 study with participants randomly assigned to one of several eloralintide doses or to placebo. It uses a parallel group, double blind design, meaning neither patients nor investigators know who is getting the active drug, and the main goal is to see if treatment helps reduce weight safely versus placebo.

The study was first submitted on 2026-01-30, marking the formal start of regulatory and site set up work. The latest update posted on 2026-02-09 signals that the protocol and key details are current, and the “not yet recruiting” status suggests first patient enrollment and primary completion milestones are still ahead.

For investors, this update underlines Lilly’s push to deepen its obesity franchise beyond current incretin blockbusters like tirzepatide, aiming to capture patients who plateau on existing drugs. If Eloralintide shows meaningful extra weight loss with good safety, it could strengthen LLY’s premium valuation and widen the gap versus obesity rivals in the U.S. and globally.

While the trial is still early and carries clinical risk, the move into Phase 3 signals Lilly’s confidence in the asset and supports long term growth expectations for its metabolic portfolio, though near term stock moves may be modest until data readouts approach. The study remains active in setup with further information and updates available on the ClinicalTrials portal.

To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.